Verteporfina en la degeneración macular

• Autores: Mª J. Agustín Ferrández, Josefa Carcelén-Andrés, Isabel Villar Fernández, U. Cilveti-Sánchez, María Ángeles Allende Bandrés
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 6, Nº. 6, 2004, págs. 375-385
• Idioma: español
• Títulos paralelos:
  • Verteporfin in macular degeneration
• Texto completo no disponible (Saber más ...)
• Resumen

  • Retrospective analysis of verteporfine use in patients admitted during 13 months with a follow-up of 21 months. The sources of data have been the clinical histories, the flourescein (FAG) and the indocyanine green (ICG) angiographies, the visual acuity (VA) and the pharmacy record of photodynamic therapy (PDT). The efficacy variables have been the variations in VA, the semiquantitative valuation of FAG and/or ICG and the possible subjective improvement. The safety variables have been the visual or systemic adverse effects. 108 patients were recruited; 75% of them suffered from exudative age-related macular degeneration (EARMD) and 25% secondary choroidal neovasculation to pathological myopia (PM). The classification by membrane type is: classic 52.8%, occult 26.8%, predominantly classic 13.9% and predominantly occult 6.5%. The lesion's location was: subfoveal in 73.2%, juxtafoveal in 25.9% and extrafoveal in 0.9%. The average size of the lesion was 1.4 papilla diameters. EARMD is a disease of bilateral affectation, although it does not always require the treatment of both eyes, only in three cases the two eyes were treated and in 42 both eyes were affected. The number of patients with a satisfactory response was 66 and without any response 42. The observed adverse reactions were few and mild